JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Radiology and endoscopic findings of silent maxillary sinus atelectasis and enophthalmos.

OBJECTIVES: The objective of this study is to discuss the presentation and surgical management of patients presenting with silent maxillary sinus atelectasis with enophthalmos (SMSAE).

STUDY DESIGN AND METHODS: We performed an analysis of prospectively collected data on patients with maxillary sinus opacification and associated enophthalmos from 1999 to 2003. Patients were evaluated based on physical examination, nasal endoscopy, and computed tomographic findings.

RESULTS: Sixty-four patients were identified with unilateral maxillary sinus opacification. Of these, 7had radiographic evidence of maxillary sinus volume reduction. Of these 7 patients, 5 had maxillary sinus atelectasis with enophthalmos, the components constituting SMSAE. The mean age of the patients was 42 years (range, 22-65). None of the patients had any history of nasal trauma or developmental defects before presentation. All 5 patients with SMSAE had uncinate retraction on nasal endoscopy. Uncinate retraction was not seen in the 2 patients without enophthalmos (chi(2) = 7, P= .008). All 7 patients with maxillary opacification were treated with endoscopic sinus surgery, with resolution of their maxillary sinus obstruction at 2 years' follow-up. Only 1 of 5 patients with SMSAE requested orbital floor reconstruction after sinus surgery performed by the oculoplastic service with resolution of enophthalmos.

CONCLUSION: All patients with SMSAE had evidence of uncinate process retraction on nasal endoscopy, whereas patients without enophthalmos did not, and the difference was statistically significant. Surgical treatment is the mainstay of therapy for this condition, with resolution of maxillary opacification at 2 years' follow-up.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app